GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » Tax Expense

Mercury Biopharmaceutical (ROCO:6932) Tax Expense : NT$0.03 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mercury Biopharmaceutical Tax Expense?

Mercury Biopharmaceutical's tax expense for the months ended in Jun. 2024 was NT$0.03 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0.03 Mil.


Mercury Biopharmaceutical Tax Expense Historical Data

The historical data trend for Mercury Biopharmaceutical's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Biopharmaceutical Tax Expense Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
- - - - -

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only - - - - 0.03

Mercury Biopharmaceutical Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mercury Biopharmaceutical  (ROCO:6932) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Mercury Biopharmaceutical Tax Expense Related Terms

Thank you for viewing the detailed overview of Mercury Biopharmaceutical's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Mercury Biopharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.

Mercury Biopharmaceutical Headlines

No Headlines